The conference highlighted recent advances in the diagnosis and management of obesity, endocrine disorders, diabetes, and growth hormone and thyroid diseases.
American Diabetes Association, June 21-24
Jul 01, 2024
The annual meeting of the American Diabetes Association was held this year from June 21 to 24 in Orlando, Florida, drawing more than 15,000 participants from around the world, including clinicians, academicians,...
Men face more diabetes complications than women
May 17, 2024
The findings were independent of diabetes duration over a 10-year period.
Reductions seen in HbA1c, body weight with once-weekly tirzepatide
Oct 06, 2023
Estimated mean change from baseline in HbA1c was −2.1% with tirzepatide, which met noninferiority criteria and achieved superiority.
Glycemic control superior with semaglutide 25 and 50 mg in Type 2 diabetes
Aug 04, 2023
Mean changes in HbA1c were significantly greater for semaglutide 25 mg or 50 mg versus 14 mg.
Mean platelet volume linked to mortality in peritoneal dialysis patients
Nov 22, 2023
MPV ≥10.2 fL was independently associated with all-cause mortality and cardiovascular mortality.
Nerve decompression may ease painful diabetic peripheral neuropathy
Mar 28, 2024
Nerve decompression was associated with reduced pain, but equal improvement was seen in decompressed and sham legs.
Durable reductions in HbA1c, body weight seen with semaglutide
Oct 04, 2023
The real-world study shows greater reductions in HbA1c and body weight for patients with a proportion of days covered ≥60%.
Disparities in stroke risk factors persist for Black adults
Aug 07, 2023
After a year of aggressive medical management, diastolic blood pressure and physical activity scores no longer differed for Blacks and non-Blacks.
ACC: Semaglutide beneficial in obesity-related heart failure, type 2 diabetes
Apr 09, 2024
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.